Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has provided an update.
AIM Vaccine Co., Ltd. has announced a board meeting scheduled for August 27, 2025, to discuss and approve the interim results for the first half of 2025, consider the recommendation of an interim dividend, and address other business matters. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry with a focus on vaccine development and production.
Average Trading Volume: 1,961,925
Technical Sentiment Signal: Hold
For detailed information about 6660 stock, go to TipRanks’ Stock Analysis page.